Goldman Sachs Group Inc Esperion Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,753,260 shares of ESPR stock, worth $5.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,753,260
Previous 1,307,668 110.55%
Holding current value
$5.01 Million
Previous $2.16 Million 180.81%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$1.61 - $3.83 $2.33 Million - $5.54 Million
1,445,592 Added 110.55%
2,753,260 $6.06 Million
Q3 2024

Nov 14, 2024
BUY
$1.61 - $2.73 $630,567 - $1.07 Million
391,657 Added 42.76%
1,307,668 $2.16 Million
Q2 2024

Aug 13, 2024
SELL
$1.84 - $3.24 $4.5 Million - $7.93 Million
-2,448,255 Reduced 72.77%
916,011 $2.03 Million
Q1 2024

May 15, 2024
BUY
$2.02 - $3.02 $4.66 Million - $6.97 Million
2,306,865 Added 218.16%
3,364,266 $9.02 Million
Q4 2023

Feb 13, 2024
SELL
$0.73 - $3.08 $87,304 - $368,352
-119,595 Reduced 10.16%
1,057,401 $3.16 Million
Q3 2023

May 14, 2024
BUY
$0.96 - $1.79 $114,811 - $214,075
119,595 Added 11.31%
1,176,996 $1.15 Million
Q3 2023

Nov 14, 2023
BUY
$0.96 - $1.79 $337,233 - $628,800
351,285 Added 42.54%
1,176,996 $1.15 Million
Q2 2023

May 14, 2024
BUY
$1.2 - $1.76 $149,460 - $219,208
124,550 Added 17.76%
825,711 $1.15 Million
Q2 2023

Aug 14, 2023
BUY
$1.2 - $1.76 $149,460 - $219,208
124,550 Added 17.76%
825,711 $1.15 Million
Q1 2023

May 14, 2024
SELL
$1.46 - $7.3 $39,678 - $198,392
-27,177 Reduced 3.73%
701,161 $1.11 Million
Q1 2023

May 11, 2023
SELL
$1.46 - $7.3 $39,678 - $198,392
-27,177 Reduced 3.73%
701,161 $1.11 Million
Q4 2022

May 14, 2024
BUY
$5.09 - $8.5 $1.34 Million - $2.23 Million
262,539 Added 56.36%
728,338 $4.54 Million
Q4 2022

Feb 13, 2023
BUY
$5.09 - $8.5 $1.34 Million - $2.23 Million
262,539 Added 56.36%
728,338 $4.54 Million
Q3 2022

May 14, 2024
BUY
$5.45 - $8.13 $1.11 Million - $1.66 Million
204,241 Added 78.09%
465,799 $3.12 Million
Q3 2022

Nov 10, 2022
BUY
$5.45 - $8.13 $1.11 Million - $1.66 Million
204,241 Added 78.09%
465,799 $3.12 Million
Q2 2022

May 14, 2024
SELL
$4.77 - $6.67 $3.8 Million - $5.31 Million
-795,843 Reduced 75.26%
261,558 $1.66 Million
Q2 2022

Aug 15, 2022
SELL
$4.77 - $6.67 $514,935 - $720,046
-107,953 Reduced 29.22%
261,558 $1.66 Million
Q1 2022

May 16, 2022
BUY
$3.34 - $5.56 $274,688 - $457,265
82,242 Added 28.63%
369,511 $1.72 Million
Q4 2021

Feb 14, 2022
BUY
$4.81 - $11.92 $1.25 Million - $3.1 Million
259,716 Added 942.61%
287,269 $1.44 Million
Q3 2021

Nov 10, 2021
BUY
$11.34 - $21.37 $312,451 - $588,807
27,553 New
27,553 $332,000

Others Institutions Holding ESPR

# of Institutions
215
Shares Held
129M
Call Options Held
1.78M
Put Options Held
1.27M
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $121M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email